成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 912999-49-6 Chemical Structure| 912999-49-6
Chemical Structure| 912999-49-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 912999-49-6

,{[proInfo.pro_purity]}

AT13387 is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity.

Synonyms: AT13387

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of Onalespib

CAS No. :912999-49-6
Formula : C24H31N3O3
M.W : 409.52
SMILES Code : O=C(C1=CC(C(C)C)=C(O)C=C1O)N2CC3=C(C=C(CN4CCN(C)CC4)C=C3)C2
Synonyms :
AT13387
MDL No. :MFCD18633198
InChI Key :IFRGXKKQHBVPCQ-UHFFFAOYSA-N
Pubchem ID :11955716

Safety of Onalespib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Onalespib

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description Reference
GMYC1 cells 0.05 μM 24 hours HSP90 inhibition led to increased levels of HSF1 and HSP70, indicating successful HSP90 inhibition and induction of cell cycle arrest and apoptosis. PMC9984535
GTML2 cells 2 μM 24 hours HSP90 inhibition did not induce significant apoptosis in GTML2 cells. PMC9984535
22Rv1 0.1 μmol/L, 0.5 μmol/L, 1 μmol/L, 2 μmol/L 48 hours To evaluate the effect of Onalespib on AR and AR-V7 protein levels, results showed that Onalespib reduced AR-FL and AR-V7 protein levels PMC4874658
VCaP 0.1 μmol/L, 0.5 μmol/L, 1 μmol/L, 2 μmol/L 48 hours To evaluate the effect of Onalespib on AR and AR-V7 protein levels, results showed that Onalespib reduced AR-FL and AR-V7 protein levels PMC4874658
LNCaP95 4 μmol/L 48 hours To evaluate the effect of Onalespib on AR and AR-V7 protein levels, results showed that Onalespib reduced AR-FL and AR-V7 protein levels PMC4874658
GSC262 0.4 μM 48 hours To evaluate the effect of Onalespib on DNA repair proteins CHK1 and RAD51, results showed a significant decrease in the levels of CHK1 and RAD51 within 16 hours, indicating that HSP90 inhibition affected DNA damage repair. PMC9064967
GSC811 0.4 μM 48 hours To evaluate the effect of Onalespib on DNA repair proteins CHK1 and RAD51, results showed a significant decrease in the levels of CHK1 and RAD51 within 16 hours, indicating that HSP90 inhibition affected DNA damage repair. PMC9064967
LN229 0.1 – 0.8 μM 24–96 h To evaluate the effect of Onalespib on glioma cell proliferation, results showed that Onalespib significantly inhibited cell proliferation in LN229, U251HF, and A172 cells. PMC5986078
U251HF 0.1 – 0.8 μM 24–96 h To evaluate the effect of Onalespib on glioma cell proliferation, results showed that Onalespib significantly inhibited cell proliferation in LN229, U251HF, and A172 cells. PMC5986078
A172 0.1 – 0.8 μM 24–96 h To evaluate the effect of Onalespib on glioma cell proliferation, results showed that Onalespib significantly inhibited cell proliferation in LN229, U251HF, and A172 cells. PMC5986078
UMSCC74B 100 nM 24 hours To assess the effect of AT13387 on the global protein abundance in UMSCC74B cells, it was found that 100 nM AT13387 significantly reduced the levels of DNA repair proteins. PMC7541797
UMSCC74B 3 μM 24 hours To assess the effect of AT13387 on the global protein abundance in UMSCC74B cells, it was found that 3 μM AT13387 significantly reduced the abundance of over 20% of the proteins. PMC7541797
HNSCC cell lines 100 nM 24 hours To assess the radiosensitizing effect of AT13387 on HNSCC cell lines, it was found that 100 nM AT13387 caused radiosensitization in all 11 cell lines used in this study. PMC7541797
FaDU cells 100 nM 24 hours To evaluate the radiosensitization effect of Onalespib on FaDU cells, results showed that Onalespib significantly enhanced the radiosensitivity of FaDU cells. PMC8286306
A549 cells 100 nM 24 hours To evaluate the radiosensitization effect of Onalespib on A549 cells, results showed that Onalespib did not significantly enhance the radiosensitivity of A549 cells. PMC8286306
UMSCC-1 cells 100 nM 24 hours To evaluate the radiosensitization effect of Onalespib on UMSCC-1 cells, results showed that Onalespib did not significantly enhance the radiosensitivity of UMSCC-1 cells. PMC8286306
H460 wtp53 cells 100 nM 24 hours To evaluate the radiosensitization effect of Onalespib on H460 wtp53 cells, results showed that Onalespib significantly enhanced the radiosensitivity of H460 wtp53 cells. PMC8286306
H460 DNp53 cells 100 nM 24 hours To evaluate the radiosensitization effect of Onalespib on H460 DNp53 cells, results showed that Onalespib significantly enhanced the radiosensitivity of H460 DNp53 cells. PMC8286306
1522 cells 100 nM 24 hours To evaluate the radiosensitization effect of Onalespib on 1522 cells, results showed that Onalespib did not significantly enhance the radiosensitivity of 1522 cells. PMC8286306
U87 cells 200 μM 60 minutes To evaluate the specificity of Onalespib for Hsp90 binding in U87 cells, results showed that Onalespib only moderately reduced intracellular [11C]SNX-ab binding. PMC9886718
BON cells 1-104 nM 72 hours To evaluate the effect of Onalespib on the viability of BON cells in monolayer culture, the results showed that Onalespib significantly reduced the viability of BON cells with an IC50 value of 27 nM. PMC6831206
NCI-H727 cells 1-104 nM 72 hours To evaluate the effect of Onalespib on the viability of NCI-H727 cells in monolayer culture, the results showed that Onalespib significantly reduced the viability of NCI-H727 cells with an IC50 value of 102 nM. PMC6831206
NCI-H460 cells 1-104 nM 72 hours To evaluate the effect of Onalespib on the viability of NCI-H460 cells in monolayer culture, the results showed that Onalespib significantly reduced the viability of NCI-H460 cells with an IC50 value of 51 nM. PMC6831206

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
mice GMYC/TetGFP/Luc cell engraftment model intraperitoneal injection 1.6 - 6.3 mg/kg twice daily for 28 days Onalespib treatment significantly extended the survival time of mice, with a median survival time of 27 days compared to 16 days in the control group. PMC9984535
NMRI nu/nu mice 22Rv1 subcutaneous solid tumor model Intraperitoneal injection 150 mg/kg Every 3 days for 17 days To evaluate the effect of Onalespib on tumor growth and AR-V7 levels, results showed that Onalespib significantly inhibited tumor growth and downregulated AR-V7 mRNA levels PMC4874658
zebrafish intracranial glioma xenograft model fish water 5 mg/kg Single dose, observed for 4 days To evaluate the effect of Onalespib in combination with radiotherapy and temozolomide, results showed that the combination treatment significantly extended the survival of zebrafish. PMC9064967
Mice Glioma xenograft model Intravenous tail vein injection 10 mg/kg Single dose, 40 minutes duration To evaluate the inhibitory effect of Onalespib on glioma in vivo, results showed that Onalespib effectively crossed the blood-brain barrier and inhibited HSP90 in vivo, extending survival in zebrafish xenografts and in combination with TMZ in both zebrafish and GSC mouse xenografts. PMC5986078
BALB/c nu/nu mice neuroendocrine tumor xenografts intra-peritoneal injection 0.4 mg/day and 10 mg/day Once daily for 72 hours or 96 hours To evaluate the efficacy of Onalespib in combination with 177Lu-DOTATATE, results showed that the combination treatment significantly delayed tumor doubling time and increased complete remission rates. PMC7075859
Mice UMSCC74B xenograft model Intraperitoneal injection 10 μM Administered on Days 7, 14, 21, and 28, continued until Day 35 To assess the pharmacokinetics and pharmacodynamics of AT13387 in the UMSCC74B xenograft model, it was found that 40 mg/kg AT13387 resulted in significantly higher concentrations in tumors compared to plasma and enhanced Hsp70 expression. PMC7541797
mice BALB/c SCID mice intraperitoneal injection 40 mg/kg Two injections, 96 hours apart Onalespib in combination with crizotinib delayed the emergence of crizotinib resistance and significantly inhibited tumor growth in the H2228 model. PMC5117788
nude mice FaDU xenograft model intraperitoneal injection 1 mg/kg Single injection, glucose tolerance test performed 18 hours later To evaluate the tumor regrowth delay effect of Onalespib in combination with fractionated radiation in the FaDU xenograft model, results showed that the combination treatment significantly delayed tumor regrowth. PMC8286306

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01246102 Solid Tumors|Breast Cancer PHASE1 COMPLETED 2017-10-27 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT02572453 Recurrent Anaplastic Large Cel... More >>l Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Refractory Anaplastic Large Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Transformed Non-Hodgkin Lymphoma Less << PHASE2 TERMINATED 2021-03-18 Los Angeles County-USC Medical... More >> Center, Los Angeles, California, 90033, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, 90033, United States|USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, 92663, United States|Keck Medical Center of USC Pasadena, Pasadena, California, 91105, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, 40536, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, 21287, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Nebraska Medicine-Bellevue, Bellevue, Nebraska, 68123, United States|Nebraska Medicine-Village Pointe, Omaha, Nebraska, 68118, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, 08903, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, 08903, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States|University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, 15232, United States|Parkland Memorial Hospital, Dallas, Texas, 75235, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, 75390, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, 84112, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.44mL

0.49mL

0.24mL

12.21mL

2.44mL

1.22mL

24.42mL

4.88mL

2.44mL

References

 

Historical Records

Categories